TGFB1 and COVID-19: In addition, with the knowledge that selenium targets immune response biomarkers, along with the data that we generated confirming that TGF-β is a selenium target by selenium concentrations that can be achieved clinically without host toxicity, as well as reports that TGF-β is overexpressed in patients with COVID-19 [88,141,142], sufficient evidence is available to evaluate the potential role of a defined selenium type and dose in the treatment of patients with COVID-19.